Crispr will also be able to nominate up to two siRNA targets for research and development, for which it would retain opt-in rights to lead commercialization, the companies said. Sirius will be ...

AbbVie and ADARx Pharmaceuticals have announced a multi-billion dollar partnership to develop small interfering RNA (siRNA) therapeutics across neuroscience, immunology and oncology. The collaboration ...

AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to access its small interfering RNA (siRNA) platform. The partnership gives ...

Late clinical-stage biotech ADARx is working on small interfering RNA, or siRNA, therapeutics, a class of molecules capable of regulating gene expression and protein production. The strategic ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license ...

Chronic hepatitis B (CHB) remains a significant global health burden, with existing therapies including nucleos(t)ide analogs, interferon, siRNA, and therapeutic vaccines demonstrating limited ...

Eli Lilly has recently announced several developments, including positive Phase 2 results for their siRNA therapy lepodisiran and the expansion of their digital healthcare platform, LillyDirect ...

They report their findings in Nanoscale ("Enhanced antifungal activity of siRNA-loaded anionic liposomes against the human pathogenic fungus Aspergillus fumigatus"). RNAi Combined with Optimized ...

Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...

Silexion is collaborating with Evonik on the development of a long-acting siRNA PLGA microparticle formulation, which has demonstrated high efficacy in preclinical models for KRAS-mutated cancers ...